The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

At the moment of publication, the compound presented is solely approved for use in the US by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The compound is still being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.

European Society of Cardiology Congress 2021 Hot Line: FIGARO-DKD & FIDELITY AnalysisAugust 27–30, 2021

FIGARO FIDELITY

Presentation of the FIGARO-DKD and FIDELITY analysis at the ESC Congress 2021

Thank you for your interest! See below to watch the session recording of the ESC FIGARO-DKD and FIDELITY hotline session, which includes two presentations where Dr. Bertram Pitt and Professor Gerasimos Filippatos discuss the data from the FIDELIO-DKD and FIGARO-DKD trials.

Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.

Finerenone
Video


Saturday 28 August, 2021 | 17:25–18:10 CEST | On Demand
Hot Line - FIGARO-DKD / FIDELITY Analysis
FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes.

Speaker: Bertram Pitt

FIDELITY Analysis: finerenone in mild-to-severe chronic kidney disease and type 2 diabetes.

Speaker: Rajiv Agarwal and Gerasimos Filippatos

Should you wish to receive further updates on the materials featured here then please follow this link to submit your details.

Play Icon

View Video (FIGARO-DKD)

Play Icon

View Video (FIDELITY)

More Information

For more information regarding Finerenone visit us by clicking the link below 
The compound presented is approved for use by the US Food and Drug Administration (FDA) in chronic kidney disease (CKD) associated with type 2 diabetes (T2D) but is investigational or being investigated for uses that have not been approved by the European Medicines Agency (EMA) and other health authorities.

Date accessed: 1 September, 2021 

Doc Icon

Visit Link

The compendium provided by Bayer is a compilation of Bayer-sponsored presentations. Copies of presentations obtained from this compendium are for personal use only and may not be reproduced or distributed without permission from European Society of Cardiology (ESC) and from the authors.

Reused with permission. © 2021 European Society of Cardiology (ESC). All rights reserved.

For any questions, please contact Medical Information at 1-888-84-BAYER (1-888-842-2937), or visit go.bayer.com/vPIR.

MA-M_FIN-ALL-0422-1

© 2022 Bayer AG

The content of this presentation is provided to an audience of international healthcare professionals from around the world for scientific discussion and scientific exchange. Bayer does not recommend the use of any drug substance outside of its approved indications.

 

At the moment of publication, the compound presented has been only approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA). For other approvals, follow your local regulations or health authorities legislation.

 

Last updated on 23/09/2021